Oncolinx, a Spin-Out of the Center for Advancing Innovation, Launches Cancer Research into Space

Oncolinx Founder and CEO, Sourav Sinha, at the Orbital ATK Cygnus Launch

This is more evidence that this amazing team will push any limit–on this planet and beyond–to improve the state of cancer care.

Oncolinx, a spin-out of the Center for Advancing Innovation (CAI) and a winner of the 43North Startup Competition, has truly taken their cancer research out of this world. On April 22, 2017, an Orbital ATK Cygnus spacecraft delivered Oncolinx’s innovative cancer experiments from Cape Canaveral to the International Space Station’s (ISS) U.S. National Laboratory, managed by the Center for the Advancement of Science in Space (CASIS). As reported by NASA in March 2017, Oncolinx’s project will evaluate the efficacy and metabolism of their proprietary antibody-drug conjugates (ADCs) in a microgravity environment, wherein cancer cells grow in three-dimensional tumor models that mimic physiological forms within the human body, and are more difficult to create in laboratories on Earth.

“We’re excited and privileged that we are able to do important cancer research aboard the International Space Station. This is more evidence that this amazing team will push any limit–on this planet and beyond–to improve the state of cancer care,” said Oncolinx Co-Founder and CEO Sourav Sinha. “We are very fortunate and grateful to be working with such a great team from NASA, United Launch Alliance, and CASIS to make this happen.”

Oncolinx’s novel cancer therapy consists of a biologically active drug, called Azonafide, which is attached to a select monoclonal antibody with the ability to specifically target malignant cancer cells. Due to its selective targeting of cancer cells, Oncolinx’s therapy can avoid adverse side effects of…

Read the full article from the Source…

Back to Top